Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2014 March;53(1) > Minerva Pneumologica 2014 March;53(1):21-6





A Journal on Diseases of the Respiratory System

Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index




Minerva Pneumologica 2014 March;53(1):21-6

language: Italian

Pidotimod activity in patients affected by COPD

Cogo R.

Responsabile UOS Riabilitazione Respiratoria, Presidio Ospedaliero “A. Zappatoni”, Cassano d’Adda, Milano, Italia


AIM: Exacerbations of chronic obstructive pulmonary disease (COPD) are frequent events both in the number of physician visits and drug prescriptions. Furthermore, age, comorbid chronic conditions and the severity of pathology often determine the hospitalization of the patient.
METHODS: According to our previous experience, we studied 85 patients affected by COPD (GOLD III) subjected to influenza vaccination in November of 2012. The patients were randomly divided in to two group and the patients of one of the two groups were treated with Pidotimod (800 mg/die for 15 days/month for 2 months). The treatment period was followed by a follow-up period of two months. The exacerbations of COPD were registered for both groups for a total period of 4 months (treatment + follow-up).
RESULTS: The results show a good efficacy of the immunostimolant treatment. In the 16 patients from the treatment group, 1 or more exacerbations were registered, compared to the 29 patients in the control group. No significant difference in the gravity of the symptoms was observed between the two group of patients.
CONCLUSION: The minor incidence of exacerbations in the treatment group results in a better quality of life, in less physician visits and/or drugs prescriptions and finally a reduction in the disease progression. It is in fact known that any exacerbation increases the decline in lung function.

top of page

Publication History

Cite this article as

Corresponding author e-mail